AI Analysis
AI-generated analysis. Always verify with the original filing.
Quantum BioPharma Ltd. announced the appointment of Dr. Salvatore Napoli, MD, as Principal Investigator for its planned Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis. The company intends to submit an IND application to the FDA in the coming weeks.
Key Takeaways
1Appointment of Dr. Salvatore Napoli as Principal Investigator for Phase 2 trial of Lucid-MS
2Lucid-MS targets demyelination in Multiple Sclerosis
3IND application to FDA planned in coming weeks
4Dr. Napoli has over 20 years of MS experience and leads Neurology Center of New England
5Lucid-MS is a first-in-class neuroprotective NCE shown to prevent demyelination in preclinical models